Figure 2e illustrated that 4Mu improved the percentage of CD3+CD4+ (5.64 ± 0.48% vs. 3.71 ± 1.43%; ns, 4Mu vs. Saline) and CD3+CD8+ T cells (35.6 ± 7.01% vs. 6.25 ± 1.34%; (***p < 0.001, 4Mu vs. Saline; Mann–Whitney Test) in tumor tissue sections from treated mice in comparison with non-treated mice We also observed that 4Mu therapy was able to induce a significant decrease of splenic Gr1+CD11b+ myeloid derived suppressor cells (MDSCs), and CD4+Foxp3+ Regulatory T cells (Tregs) levels in HCC-bearing mice (Supplementary Fig. S2). The gene discussed is ITGAM; the disease is hepatocellular carcinoma.